KPV (Lys-Pro-Val, lysine-proline-valine) is a short synthetic tripeptide that matches the three C-terminal amino-acid residues of alpha-melanocyte-stimulating hormone (α-MSH), the α-MSH(11–13) fragment. α-MSH is a natural neuropeptide of the melanocortin family, well known for its role in pigmentation and, beyond that, for pronounced anti-inflammatory and immunomodulatory properties. Research interest in KPV arose precisely because this minimal sequence keeps a large part of the anti-inflammatory activity of the full hormone without causing pigmentary effects [1].

What it is and its class

Chemically, KPV is a linear tripeptide with the molecular formula C₁₆H₃₀N₄O₄ and a molar mass of about 342 g/mol. It is treated as a melanocortin-derived peptide and a convenient model compound for studying which structural elements of α-MSH are responsible for the anti-inflammatory action. Unlike large proteins, KPV is a short, well-defined, reproducible molecule, which makes it suitable for in vitro laboratory experiments and animal models [1].

Mechanism of action (from the available data)

The KPV mechanism is only partly understood and mainly from cell and animal models. Several directions are described:

  • Intracellular suppression of inflammatory signals. Several studies link KPV to reduced activation of the transcription factor NF-κB and lower production of pro-inflammatory cytokines in immune-system and epithelial cells [1].
  • Transport via PepT1. In intestinal epithelial cells KPV can enter through the oligopeptide transporter PepT1; it then acts directly on intracellular inflammatory pathways, lowering the inflammatory response in colon cell cultures [2].

Note: these mechanisms are described mostly in experimental systems and should not be automatically transferred to the human body.

What has been studied

The main body of data concerns intestinal inflammation. In preclinical studies on (chemically induced) mouse colitis models, giving KPV reduced the severity of inflammation, body-weight loss, and histological signs of mucosal damage [2][3]. Later work studied targeted delivery of KPV, for example orally with functionalised nanoparticles, to raise the local concentration in the colon in ulcerative colitis models [4].

The second direction is skin and other tissues. Since KPV derives from α-MSH, it is studied in the context of skin inflammation and healing; review articles describe the anti-inflammatory and protective effects of α-MSH and related tripeptides in various tissues [1]. Specific clinical evidence for human skin, however, is lacking.

Safety and limitations

The human safety profile of KPV has not been systematically established. In preclinical work the short peptide was usually well tolerated, but that is not the same as proven safety in humans: the doses, routes, and duration in animal experiments do not match clinical conditions. There are no long-term data and no data on drug interactions or reproductive safety in humans.

The honest level of evidence

As of today the KPV evidence base is mainly preclinical (cell cultures and rodent models). Quality randomised controlled clinical trials (RCTs) confirming the efficacy and safety of KPV in humans for any indication are lacking. So it is fair to describe KPV as a promising research subject with a plausible anti-inflammatory mechanism rather than an agent with a proven clinical effect. Any claim of "treating" bowel or skin disease with KPV has no sufficient basis at this stage.

Form and handling (research-use)

Longeva supplies KPV strictly as a research substance (reagent) with an accompanying certificate of analysis (COA). It is not a medicine and is not intended to diagnose, treat, or prevent any disease in humans or animals.

The typical form is a white lyophilised powder in a vial, reconstituted with sterile solvent immediately before laboratory use. The lyophilisate is stored protected from light and moisture; the reconstituted solution is kept cold and used within a short window. Handling, storage, and disposal must follow laboratory safety rules and applicable law, and all work is done by qualified personnel under controlled conditions.